1) Today's NEJM has lot's of interesting stuff. First up, they have a review of the first cases of fungal infections associated with contaminated methylprednisolone injections in Tennessee. The report covers 66 case patients with 21 having confirmed Exserohilum rostratum infection and 1 having confirmed Aspergillus fumigatus infection.
2) Next up, NEJM has a perspective piece from the FDA that highlights infections secondary to contaminated antiseptic products including iodophors, alcohol products, CHG and quaternary-ammonium compounds.
3) And finally from the NEJM, Thomas Sandora and Donald Goldmann have a perspective piece outlining their suggestions for preventing hospital outbreaks of antibiotic-resistant bacteria. Most of what they offer is standard infection control dogma from the - it's the healthcare worker's fault for not washing his/her hands diatribe - to the suggestion that a "parsimonious set of interventions aimed at reducing exposure to antibiotics may have the greatest effect on resistance." They even included a table of the suggested parsimonious stewardship interventions (below). I don't believe that any are backed by more than uncontrolled quasi-experimental studies or expert opinion. (Please correct me if I'm wrong!) Might they have recommended funding studies of these interventions instead? It's hard enough to be a hospital epidemiologist in 2012 marketing the few evidence-based interventions at our disposal without laying the burden of making us defend interventions based on pure speculation on our backs. Oh well.
4) There is a report in today's Ottawa Citizen by Helen Branswell that nicely outlines two NDM-1 outbreaks that occurred (October 2011 and January 2012) in Toronto. The article covers an study published in ICHE and another in CID. The latter described the transmission of the NDM-1 between E. coli and Klebsiella species in the same patient.
5) Last-but-not-least, check out this story in NPR that highlighted an innovative research study out of Michigan State University. Researchers modeled the spread of murders in Newark, NJ as an infectious disease and discovered that murder appears to be transmissible like an infectious pathogen. They are now figuring out why some neighborhoods are more resistant to homicide and how they might "vaccinate" populations to reduce murder. Pretty cool and Go Sparty!
Pondering vexing issues in infection prevention and control
Showing posts with label Exserohilum. Show all posts
Showing posts with label Exserohilum. Show all posts
Thursday, December 6, 2012
Monday, October 29, 2012
Fungal meningitis outbreak still unfolding
The fungal meningitis outbreak continues to expand. At this point, there are 347 cases of central nervous system infection (meningitis or stroke) and 7 joint infections, with 25 deaths. The outbreak now involves 18 states with an estimated 14,000 patients exposed to contaminated methylprednisolone from the New England Compounding Center. Exserohilum has been recently cultured from unopened vials of the product and is the predominant pathogen in the outbreak.
Here are some recent articles on the outbreak:
Here are some recent articles on the outbreak:
- Wall Street Journal (10/28/12)
- Boston Globe (10/28/12)
- New York Times (10/28/12)
Sunday, October 14, 2012
Fungal Meningitis Update
It has been a few days since Mike last blogged on this curious but devastating outbreak, and time to mention a few developments. First off, it is now clear that the outbreak isn’t primarily due to Aspergillus, but rather to a little-known soil (or dematiaceious) fungus called Exserohilum rostratum. The Mycology Online site at the University of Adelaide is an excellent quick guide to the gory details of identification (be sure to look carefully for the ellipsoidal to fusiform poroconidia that are formed apically on a sympodially elongating geniculate conidiophore!).
Exserohilum are common environmental molds, and rarely cause human disease. Slow-growing and challenging to identify in the lab, it would be difficult to imagine an agent that would be more insidious and refractory to diagnosis and treatment once injected into an immune-privileged site. This is why the number of cases continues to increase long after the compounding pharmacy responsible for distribution has been shut down (and also why treatment may not be effective by the time a case is recognized).
Finally, I wanted to highlight the fact that your IDWeek planners have been working overtime to put together a late-breaker session at IDWeek to update all attendees on this outbreak. We will have representation from CDC, a clinical mycologist, and a clinician involved in the care of affected patients. So if you are heading to San Diego please attend!
Subscribe to:
Posts (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
Back on clinical service again and having more thoughts on poor hospital design. Last month I wondered why there were no stethoscope wipe...
-
Those that follow me on twitter or the blog have probably noticed my recent focus on trying to understand the emergence of compulsory influe...
-
REUTERS/Athit Perawongmetha With the assistance of a great supply management team, we have been able to outfit all of our clinical staff wit...

